• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Gene Therapy for Melanoma Using Artificial Antibody/DNA Complex

Research Project

Project/Area Number 09671815
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Ophthalmology
Research InstitutionKEIO University

Principal Investigator

OHTAKE Yuichiro  School of Medicine, KEIO University Instructor, 医学部, 助手 (30233159)

Co-Investigator(Kenkyū-buntansha) SHIMIZU Nobuyoshi  School of Medicine,KEIO University Professor, 医学部, 教授 (50162706)
TAKAYANAGI Atsushi  School of Medicine,KEIO University Instructor, 医学部, 助手 (80245464)
MASHIMA Yukihiro  School of Medicine,KEIO University Associate Professor, 医学部, 助教授 (40157186)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1998: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1997: ¥1,700,000 (Direct Cost: ¥1,700,000)
Keywordsmelanoma / intra ocular tumor / gene therapy / monoclonal antibody / artificial antibody / immunogene
Research Abstract

The Fab fragment of monoclonal antibody B4G7 against human epidermal growth factor (EGF) receptor was conjugated with a cationic poly-L-lysine and the resulting conjugate was further complexed with reporter genes or therapeutic genes. This Fab/DNA complex was designated as "Fab immunogene". The Fab immunogene transfer in vitro was mediated through the EGF receptors in two melanoma cell lines as measured for the expression of β-galactosidase (β-Gal) gene. The frequency of β-Gal gene expressing cells was approximately 1%. The induction of suicide effects after Fab immunogene transfer of herpes simplex virus thymidine kinase (TK) or Escherichia coli cytosine deaminase (CD) gene was quite remarkable, inhibiting the growth of melanoma cells for over 7 days in the presence of ganciclovir or 5-fluorocytosine (5-FC) .
Similarly, when melanoma cells treated in vitro with the Fab immunogene carrying TK or CD were transplanted into the back of nude mouse, subsequent systemic administration of GCV or 5-FC effectively suppressed the growth of tumors, indicating the in vivo suicide effects.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Yuichiro Ohtake: "Exvivo delivery of Suicide Genes into Melanoma Cells Using Epidernal Growth Factor Receptor-specific Immunogene"Japanese Journal of Cancer Research. 90. 460-468 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 大竹雄一郎: "レセプター抗体による導入遺伝子の標的化"臨床免疫. 33. 469-474 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ohtake Y., Chen, J., Gamou, S., Takayanagi, A., Mashima Y., Oguchi Y. and Shimizu, N.: "Ex vivo Delivery of Suicide Gene into Melanoma Cells Using Epidermal Growth Factor-specific Fab Immunogene"Jpn. J. Cancer Res.. 90:. 460-468 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yuichiro OHTAKE、Atsushi TAKAYANAGI, and Nobuyoshi Shimizu: "Targeting Gene Delivery by Receptor Antibody"Clinical Immunology. 66:. 469-474 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi